Home › Cancro al rene (carcinoma a cellule renali) › Oregon › Portland
Studi clinici su Cancro al rene (carcinoma a cellule renali) a Portland, OR
11 studi su Cancro al rene (carcinoma a cellule renali) cercano partecipanti presso sedi a Portland e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · a 12 mi di distanza
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
In reclutamentoFase 1
- Exelixis Clinical Site #51, Portland
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
In reclutamentoFase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
In reclutamentoFase 1/2
- Northwest Cancer Specialists, P.C., Portland
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
In reclutamentoFase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- e altri 1
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
A Study of MGC026 in Participants With Advanced Solid Tumors
In reclutamentoFase 1
- Providence Cancer Institute, Portland
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
In reclutamentoFase 1/2
- Oregon Health & Science University (3485 S. Bond), Portland
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
In reclutamentoFase 4
- OHSU Knight Cancer Institute, Portland
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
In reclutamentoFase 1
- Oregon Health & Science University, Portland
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
In reclutamentoFase 3
- Kaiser Permanente Northwest, Portland
- Oregon Health and Science University, Portland
Studi su Cancro al rene (carcinoma a cellule renali) in altre città
- Houston, TX35 studi
- New York City, NY27 studi
- Nashville, TN23 studi
- Dallas, TX23 studi
- St. Louis, MO23 studi
- Los Angeles, CA20 studi
- Boston, MA16 studi
- Baldwin Park, CA16 studi
- Pittsburgh, PA15 studi
- Philadelphia, PA15 studi
- Queens, NY15 studi
- Cleveland, OH14 studi
Altri studi a Portland
- Cancro del polmone non a piccole cellule46 studi
- Cancro (tutti i tipi)34 studi
- Cancro al seno33 studi
- Cancro alla prostata33 studi
- Cancro metastatico29 studi
- Cancro colorettale28 studi
- Cancro ovarico27 studi
- Cancro ai polmoni26 studi
- Leucemia mieloide acuta25 studi
- Cancro dell'endometrio24 studi
- Carcinoma a cellule squamose della testa e del collo19 studi
- Cancro pancreatico19 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.